MENU
BMY
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

BMY stock forecast, quote, news & analysis

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders... Show more

BMY
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for BMY with price predictions
Aug 12, 2026

Aroon Indicator for BMY shows an upward move is likely

BMY's Aroon Indicator triggered a bullish signal on August 12, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 193 similar instances where the Aroon Indicator showed a similar pattern. In of the 193 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 15, 2026. You may want to consider a long position or call options on BMY as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BMY moved out of overbought territory on August 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where BMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BMY turned negative on August 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

BMY broke above its upper Bollinger Band on July 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.831) is normal, around the industry mean (19.693). P/E Ratio (14.031) is within average values for comparable stocks, (31.410). Projected Growth (PEG Ratio) (2.252) is also within normal values, averaging (11.441). Dividend Yield (0.039) settles around the average of (0.029) among similar stocks. P/S Ratio (2.646) is also within normal values, averaging (4.105).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. BMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.

A.I.Advisor
published Dividends

BMY paid dividends on August 03, 2026

Bristol-Myers Squibb Co BMY Stock Dividends
А dividend of $0.63 per share was paid with a record date of August 03, 2026, and an ex-dividend date of July 02, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 197.8B. The market cap for tickers in the group ranges from 72.83K to 1.09T. LLY holds the highest valuation in this group at 1.09T. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 2%. MIRA experienced the highest price growth at 12%, while NSRX experienced the biggest fall at -2%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -33%. For the same stocks of the Industry, the average monthly volume growth was -5% and the average quarterly volume growth was -29%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 30
P/E Growth Rating: 56
Price Growth Rating: 43
SMR Rating: 54
Profit Risk Rating: 63
Seasonality Score: -40 (-100 ... +100)
View a ticker or compare two or three
BMY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceuticals products

Industry PharmaceuticalsMajor

Profile
Details
Industry
Pharmaceuticals Major
Address
Route 206 and Province Line Road
Phone
+1 609 252-4621
Employees
34100
Web
https://www.bms.com
Aroon Indicator for BMY shows an upward move is likely